Tuesday, October 29, 2013 10:33:38 AM
Co announced that it concluded a productive meeting with the FDA earlier today, October 28, 2013. Parker H. Petit, Chairman and CEO, said, "We were pleased to have had the opportunity to present to the FDA our basis for concluding that our micronized products are minimally manipulated and meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 of the FDA's regulations. The FDA acknowledged that our presentation included new information that they would review and consider, and they committed to responding in a timely fashion. We hope that, upon further analysis, the FDA will agree with our position. In all events, we are committed to continuing to work with the Agency to agree on a regulatory solution to ensure that our micronized products are available for patients who can benefit from their clinical effectiveness. These solutions could include, among other things, one or more of the following: labeling changes, changes to the product, changes to the process, or submission of a Biologics License Application."
Recent MDXG News
- MIMEDX Announces First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/30/2024 08:01:00 PM
- MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- MIMEDX Introduces E-Commerce and Account Management Platform • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:28:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:11:28 PM
- MIMEDX Announces Appointment of Two New Independent Directors • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:22:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:02:35 PM
- MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:40:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:55:24 PM
- MIMEDX to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:22:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 08:11:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:13:13 PM
- MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28 • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:09:53 PM
- MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing • GlobeNewswire Inc. • 01/22/2024 01:00:00 PM
- MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook • GlobeNewswire Inc. • 12/29/2023 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM